US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Interim Report first quarter 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.First quarter (January 1, 2026-March 31, 2026) · Operating income amounted to SEK 2.8 million (3.4). · Net sales amounted to SEK 2.7 million (3.3), of

NextCell Pharma AB (publ) Annual General Meeting 2026

On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.Presentation by the

NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.NextCell’s specialism in cell therapy using umbilical cord mesenchymal stromal cells (MSC) and FUJIFILM Biosciences, a global leader in the life science market, today announced the global commercial launch from their strategic collaboration. The offering consists of FUJIFILM Biosciences PRIME-XV MSC Expansion XSFM medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product

ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Phase II clinical trial evaluating ProTrans® (allogeneic Wharton’s Jelly-derived mesenchymal stromal cells) for respiratory complications associated with COVID-19 has been accepted for publication in Cytotherapy 00736-X/abstract), the official journal of the International Society for Cell & Gene Therapy.The study, titled “Umbilical Cord Mesenchymal Stromal Cells for Respiratory Complications of COVID-19 Infection (ProTrans): Phase II Randomized Clinical Trial,” reports

NextCell Pharma presents historical quarterly figures

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.During the

NextCell publishes Year-End Report 2024/2025

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Year-End Report for the extended financial year September 1, 2024 – December 31, 2025. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year for the fourth quarter (October-December 2024) and twelve months (the previous fiscal year September 2023 - August 2024).Fourth quarter (2025-10-01 to 2025-12-31) · Operating income amounted to 1,826 (3,

NextCell Participating in JETRO’s Japan Entry Acceleration Program

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.JEAP operates a global and highly selective admission process. NextCell was selected in competition with companies from leading life science

Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.· Durable effect observed ≥7 years from first infusion · Sustained preservation of endogenous insulin production at group level · Clear dose-dependent trends over long-term follow-up At the latest follow-up, patients in

NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.During the second half of 2025, NextCell conducted a comprehensive pre-study covering regulatory, clinical, manufacturing

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.RIGHT TO PARTICIPATE AT THE GENERAL MEETING Shareholders who wish to attend the meeting must: i. both be recorded in the share register maintained by Euroclear Sweden AB on the record date, which is Monday, 2[nd] of February 2026; andii. not later than on Wednesday, 4[th] of

NextCell decides to propose a directed share issue of SEK 15 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “

Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.· Durable effect ≥6 years · Approximately 50% of insulin-producing function preserved · Strategy confirmed: a single infusion may be

NextCell in Swedish Life Science Delegation to Hong Kong

NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).Hong Kong is rapidly positioning itself as an international hub for regulatory innovation, clinical research, and capital markets, while serving

NextCell initiates collaboration with OptiCell – strengthening its cell-handling operations

NextCell Pharma AB (“NextCell” or “the Company”) has entered into a collaboration agreement with OptiCell Solutions AB (“OptiCell”) regarding the handling, freezing, storage, and transport of cell products used for research and development. The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects.“The collaboration with OptiCell fits perfectly into our daily operations. We utilise existing staff and equipment within NextCell and will also purchase services from our subsidiaries QVance

NextCell Pharma appoints Eric Gustafsson as new CFO

NextCell Pharma AB (“NextCell” or “the Company”) today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and industrial expansion phases within the pharmaceutical industry, Eric brings both strategic and operational expertise that will further strengthen NextCell’s continued growth and development.Eric Gustafsson has a master's degree in economics and finance and a broad and versatile experience in finance, manufacturing and business development from the international CDMO and pharmaceutical

NextCell Pharma company presentations

NextCell Pharma AB's ("NextCell" or the "Company") CEO Mathias Svahn gave a presentation at the BioStock Life Science Summit 2025 in Lund on November 13[th]. He will also present at Redeye Theme: Autoimmune and Inflammatory Diseases Event later today at 13:05.The presentations can be viewed at: BioStock Life Science Summit (on demand): https://biostock.se/2025/11/nextcell-pharma-life-science-summit-2025/ Redeye Theme: Autoimmune and Inflammatory Diseases (live): https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2

NextCell Pharma publishes its Interim Report 4 2024/2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 – August 31, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. . Please note that the Company's financial year is now 1 January - 31 December. This means that for the year 2025, this Q4 report will be followed by a Year-end report at the end of February 2026,

NextCell Pharma AB announces CFO transition

NextCell Pharma AB (“NextCell” or the “Company”) today announces that the Company’s CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout the notice period to ensure a smooth transition. The recruitment process to identify a successor for the CFO position has been initiated.What was initially intended as a one-year interim solution developed into four years of close collaboration, during which Patrik played a central role in building NextCell Pharma AB into a group comprising the subsidiaries Cellaviva and QVance. “We would

NextCell Pharma publishes its Interim Report 3 2024/2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 – May 31, 2025. This English version of the Interim Report is a translation of the Swedish version. The Swedish version is the official version.The report is available on the company's website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Third Quarter (2025-03-01 to 2025-05-31) · Operating income

NextCell Highlighted in FUJIFILM’s Strategic Vision, According to GEN

NextCell Pharma AB (“NextCell” or “the Company”) is pleased to announce that its strategic collaboration with FUJIFILM Biosciences has been highlighted in an article published on 8 July by Genetic Engineering & Biotechnology News (GEN). The article covers FUJIFILM’s recent rebranding and long-term ambition to act as a full-spectrum partner to drug and vaccine developers throughout the entire development cycle.The article, published by GEN – one of the top-ranked biotechnology industry publications, with a global readership of over 870,000 – recognises NextCell as part of FUJIFILM’s

Republishing of: NextCell announces strategic collaboration with FUJIFILM Biosciences

NextCell Pharma AB’s ("NextCell" or "the Company") has entered into a strategic collaboration with FUJIFILM Biosciences Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions.As part of the rebranding of Fujifilm Irvine Scientific to FUJIFILM Biosciences, we are re-publishing the press release originally issued

All Patients Successfully Treated in ProTrans-Young Study

NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion of patient dosing in the company’s largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the Company’s lead cell therapy candidate, ProTrans, in paediatric and adolescent patients with recently diagnosed type 1 diabetes.“We are pleased to have completed treatment of all patients in the ProTrans-Young study,” said Mathias Svahn, CEO of NextCell Pharma. “This is

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe